• REALIZING THE POTENTIAL OF ANTIBODY-DRUG CONJUGATES 2023
    By Published On: June 1, 2023Categories:

    Antibody-drug conjugates (ADCs) have long been described as a promising component of the industry’s oncology toolkit. The specificity of ADCs has allowed them to meet the growing demand for targeted, safer treatment options for cancer patients. However, their complex nature has led to some challenges when approaching the development and manufacturing of ADCs.

  • Unleashing the power of innovation in CDMOs through customer-Centricity and culture of service 2023
    By Published On: April 24, 2023Categories:

    Innovation is essential for the success of any pharmaceutical organization, and Contract Development and Manufacturing Organizations (CDMOs) are “innovation drivers” for major pharmaceutical companies. CDMOs “Execute the Innovation Plan” by collaborating closely with pharmaceutical companies to understand their unique needs and offer tailored solutions through prioritizing customer service.

  • Studies on the Stability of Corticosteroids: Degradation of Clobetasol Propionate, Desonide and Hydrocortisone in Topical Formulations by HPLC and UPLC-MS/MS
    By Published On: April 1, 2020Categories:

    Corticosteroids are the most widely used class of anti-inflammatory medications in the pharmaceutical industry. There are several pharmaceutical dosage forms available using different corticosteroids.

  • IMPURITY OF FAMOTIDINE 2016
    By Published On: December 29, 2016Categories:

    BACKGROUND OF THE INVENTION

    0001 (a) Field of the Invention 0002 The present invention relates to a new impurity of famotidine. The invention is further related to a process for preparing and isolating this impurity, and analytical methods for its identification, synthesis and characterization. The new impurity is also useful as a reference marker for analysis of famotidine and pharmaceutical compositions thereof. 0003)(b) Description of the Related Art 0004 Famotidine is a histamine H2-receptor antagonist chemically known as N-(aminosulfonyl)-3-2-(diamin omethylene) amino-4-thiazolyl methyl thio propanimid amide.

  • Drug-Excipient Interactions: Case Studies and Overview of Drug Degradation Pathways
    By Published On: January 28, 2016Categories:

    The objective of the current research article is to provide a comprehensive review of excipients impact on the stability of the drug product and their implications during the product development.

  • FORCED DEGRADATION STUDIES: PRACTICAL APPROACH -OVERVIEW OF REGULATORY GUIDANCE AND LITERATURE FOR THE DRUG PRODUCTS AND DRUG SUBSTANCES
    By Published On: May 19, 2013Categories:

    The Objective of the review article is to give a detailed description of the forced degradation studies as per the regulatory guidelines that are associated with various regulatory agencies.